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Abstract The risk of developing atrial fibrillation (AF)
and the risk of stroke both increase with advancing
age. As such, many individuals have, or will develop,
an indication for oral anticoagulation to reduce the
risk of stroke. Currently, a large number of antico-
agulants are available, including vitamin K antago-
nists, direct thrombin or factor Xa inhibitors (the last
two also referred to as direct oral anticoagulants or
DOACs), and different dosages are available. Of the
DOACs, rivaroxaban can be obtained in the most dif-
ferent doses: 2.5mg, 5mg, 15mg and 20mg. Many
patients develop co-morbidities and/or undergo pro-
cedures that may require the temporary combination
of anticoagulation with antiplatelet therapy. In daily
practice, clinicians encounter complex scenarios that
are not always described in the treatment guidelines,
and clear recommendations are lacking. Here, we
report the outcomes of a multidisciplinary advisory
board meeting, held in Utrecht (The Netherlands) on
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Introduction
Oral anticoagulation enables effective stroke preven-
tion in patients with atrial fibrillation (AF) who are
at risk for this severe complication. Based on the
CHA2DS2-VASc score, patients with AF are advised
whether or not to start anticoagulation [1]. The
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downside of using anticoagulation is a continuous
risk of bleeding, and this risk impacts on quality of
life and negatively influences drug adherence [2].
Previous AF guidelines used the HAS-BLED score to
assess the risk for anticoagulation-associated bleed-
ing [1]. However, the latest European guidelines on
the management of AF did not include this partic-
ular score, but recommend evaluation of individual
bleeding risk factors, and where possible treatment
of the individual bleeding risk factors [1]. With the
increasing number of co-morbidities and interven-
tions in the ageing population, such as stroke, cancer
and percutaneous coronary intervention or periph-
eral arterial interventions, complex clinical scenarios
frequently arise, which require individualised deci-
sion making. Examples of complicated scenarios
are: patients with stable coronary artery disease and
percutaneous coronary intervention, patients with
intracranial haemorrhage or recurrent bleeding in
whom there is doubt about how and when to re-start
anticoagulation, management of anticoagulation in
those with active malignancy and AF. Most of those
scenarios are not fully covered by current guidelines
and clear recommendations are lacking. Medical
management is further complicated by the availabil-
ity of a broad spectrum of antithrombotic agents,
including four different direct oral anticoagulants
(DOACs). In the absence of clear recommendations,
a multidisciplinary panel was instituted to discuss
complex clinical situations, guided by available ev-
idence from randomised controlled trials, post hoc
analyses, and cohort and registry studies. This pa-
per summarises the clinical situations discussed and
formulates recommendations for decision making.
Clinical situation A: chronic coronary artery
disease (following percutaneous coronary
intervention) and AF
Clinical case scenario
A 62-year-old woman with known paroxysmal AF
and hypertension undergoes coronary angiography
for angina and documented ischaemia. The coro-
nary angiogram shows a significant stenosis for which
a percutaneous coronary intervention (PCI) is per-
formed. What would be the best anticoagulation
strategy to pursue?
What is in the European Society of Cardiology
guidelines?
In the most recent (2016) European Society of Car-
diology (ESC) guidelines for the management of AF,
a flowchart is provided for tailoring of anticoagulation
after PCI in patients with AF (Fig. 1; [1]). The guideline
committee, as well as our expert panel, suggest that
patients with AF at risk for stroke, those withmechani-
cal valves and those with recent or recurrent deep vein
thrombosis or pulmonary embolism should continue
oral anticoagulation during and after stenting [1, 3].
In general, a short period of triple therapy (oral an-
ticoagulation, acetylsalicylic acid, P2Y12 inhibitor) is
recommended, followed by a period of dual therapy
(oral anticoagulation plus a single antiplatelet agent)
[1, 3].
Background
The ESC guidelines for the management of AF suggest
that dual antiplatelet therapy (DAPT, i.e. acetylsali-
cylic acid+ P2Y12 inhibitor) is indicated in patients
using oral anticoagulation in whom a PCI is per-
formed. However, triple therapy (DAPT plus oral
anticoagulation) is associated with a significantly in-
creased risk of major bleeding. For example, the
WOEST trial demonstrated that an approach without
acetylsalicylic acid—in that trial a vitamin K antag-
onist (VKA) combined with clopidogrel significantly
reduces bleeding risk during follow-up (19% for pa-
tients with dual therapy compared to 44% for those
with triple therapy) [4]. However, when this trial was
conducted, DOACs had not yet been introduced in
the clinical setting. The effectiveness and safety of
anticoagulation with the use of a DOAC (rivaroxa-
ban) combined with acetylsalicylic acid or DAPT was
compared with VKAs in the PIONEER AF-PCI study
[5]. The study’s main conclusion was that the ad-
ministration of either low-dose rivaroxaban (15mg
o.d.) plus a P2Y12 inhibitor for 12 months or very-
low-dose rivaroxaban (2.5mg b.i.d.) plus DAPT for 1,
6, or 12 months was associated with a lower rate of
clinically significant bleeding compared to standard
therapy with a VKA (16.8% vs 18.0% vs 26.7%, respec-
tively) plus DAPT for 1, 6, or 12 months [5]. Although
the study was not powered to assess the outcomes of
survival, myocardial infarction and stroke, no differ-
ence was observed in the incidence of these events
among the three groups. Notably, the occurrence of
stroke was very low (6.5% vs 5.6% vs 6.0%, respec-
tively), although this is partly explained by the exclu-
sion of patients with a history of stroke or transient
ischaemic attack. In the original ROCKET AF trial the
lower dose of rivaroxaban (15mg o.d.) was used only
in patients with moderate kidney disease (creatinine
clearance 30–49ml/min) [6, 7]. However, when ob-
serving registry data, it appears that the 15-mg dose
is often prescribed in clinical practice, even in those
patients with normal kidney function [8]. It is unclear
why this choice is made by treating physicians, but it
is likely due to a perceived feeling or the actual pres-
ence of risk factors for bleeding, including advanced
age and relevant co-morbidities. Importantly, one
registry showed that the use of reduced doses of apix-
aban (2.5mg b.i.d.) or rivaroxaban (15mg o.d.) was
associated with an increased risk of death, compared
to warfarin, emphasising the need to prescribe the
correct dosage for each DOAC [9]. The RE-DUAL PCI
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Fig. 1 Flowchart. Atrial




ACS acute coronary inter-
vention, OAC oral anticoag-
ulation. Reproduced from
[1], with permission
study randomised 2725 patients with AF and a PCI
to either triple therapy (dabigatran 110 or 150mg
b.i.d., acetylsalicylic acid and warfarin) or dual ther-
apy consisting of dabigatran 110 or 150mg b.i.d. plus
a P2Y12 inhibitor (clopidogrel or ticagrelor) and no
acetylsalicylic acid. Dual therapy was non-inferior to
triple therapy with respect to the risk of thromboem-
bolic events [10]. Also, in the AUGUSTUS trial of
patients with AF undergoing a PCI, the combination
of a P2Y12 inhibitor with full-dose apixaban resulted
in less bleeding and fewer hospitalisations without
significant differences in the incidence of ischaemic
events compared to regimens that included a VKA,
acetylsalicylic acid, or both [11]. Finally, these find-
ings are also confirmed in the edoxaban-based versus
VKA-based antithrombotic regimen after successful
coronary stenting in patients with AF (ENTRUST-AF
PCI) for the use of edoxaban as compared with VKA
[12]. A recent meta-analysis of the aforementioned
studies confirmed the finding that dual therapy with
a DOAC and P2Y12 inhibitor led to a reduction in
major and intracranial bleedings. However, a higher
risk of cardiac (mainly stent-related) ischaemic oc-
currences was observed [13]. Therefore in the case of
a high ischaemic risk (e.g. acute clinical presentation,
or certain difficult anatomical or procedural features),
as recommended by the ESC revascularisation guide-
lines, triple therapy may be continued for a longer
period of time (6 months) [14]. A longer duration of
triple therapy is also often required in patients with
acute coronary syndromes; however, these patients
were beyond the scope of this article, and detailed
recommendations may be found in the respective
ESC guidelines [15, 16]. For example, for a patient
admitted with a non-ST-elevation acute coronary
syndrome and a low to intermediate bleeding risk
(as assessed by the HAS-BLED score) triple therapy
is recommended for 6 months. In the case of a high
bleeding risk the period of triple therapy is reduced
to 4 weeks [15].
Consensus of advisory board
The expert panel opinion was that the optimal ap-
proach for patients with AF who have undergone PCI
should be dual therapy and the full permissible dosage
of any DOAC. There was also consensus that in the
case of rivaroxaban the choice of a lower dosage is to
be considered based on the findings of the PIONEER
AF-PC trial, but only in patients without a history of
stroke or transient ischaemic attack. For the other
DOACs, no data are available about the efficacy of
lower doses or their safety as regards stroke preven-
tion. Nonetheless, when a patient is considered to be
at a higher risk for bleeding (for any reason) that out-
weighs the stroke risk, a lower dose of a DOAC seems
reasonable. Conversely, in a patient at low risk for
bleeding, a full dose of a DOAC should be the standard
approach, depending obviously on kidney function.
Clinical situation B: stable lower extremity
arterial disease and AF
Clinical case scenario
A 56-year-old man with AF without co-morbidities is
seen by the vascular surgeon at the outpatient clinic.
The surgeon diagnoses the patient with symptomatic
peripheral artery disease (PAD) and consults the treat-
ing cardiologist regarding the consequences of this di-
agnosis for antithrombotic management. What would
be the best anticoagulation strategy to pursue for this
patient?
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Fig. 2 Flowchart. Lower
extremity arterial disease/
peripheral artery disease
(LEAD/PAD) and AF. DAT
dual antithrombotic ther-
apy, OAC oral anticoagula-
tion. Reproduced from [17],
with permission
What is in the ESC guidelines?
The 2017 ESC guideline on the diagnosis and treat-
ment of PAD includes a section on patients with AF
(Fig. 2; [17]). Except for recent peripheral artery stent-
ing, patients with PAD and AF should mostly remain
on oral anticoagulation alone, without the addition of
antiplatelet therapy. No specific recommendation re-
garding DOACs (or dosages) is made in this guideline.
Background
The CHA2DS2-VASc score used in all patients with
AF to assess stroke risk includes vascular disease
as a component [18]. Hence, patients with AF and
a history of PAD have an indication for the AF dose of
a DOAC [1]. The most recent PAD guideline of the ESC
was released in 2017 [17]. The flowchart presented
in this guideline shows that in a(n) (a)symptomatic
patient with AF and PAD who requires long-term
anticoagulation it is sufficient to continue oral anti-
coagulation monotherapy [17].
Consensus of advisory board
The suggestion of this advisory board is that in
a (highly) symptomatic PAD patient, despite intensive
walking therapy, addition of a single antiplatelet ther-
apy might be considered with background therapy
with a DOAC, in particular in patients in whom revas-
cularisation is performed. The duration of such dual
therapy should be balanced with bleeding risk and
preferably be as short as clinically feasible. Never-
theless, this certainly is an area where more research
is greatly needed. For instance, the recently pub-
lished AFIRE trial (addition of antiplatelet therapy to
rivaroxaban versus rivaroxaban monotherapy in pa-
tients with AF and stable coronary artery disease) was
stopped prematurely because of an increased mor-
tality rate in patients treated with dual therapy [19].
In conclusion, in patients with AF and stable PAD
full-dose monotherapy with a DOAC is a reasonable
alternative to a VKA in most patients.
Clinical situation C: stroke in patients with AF
Clinical case scenario
A 76-year-old women with AF (CHA2DS2-VASc score
of 5) who is using a DOAC for stroke prevention is ad-
mitted to the emergency department with stroke-like
symptoms. After performing a CT scan, the diagnosis
of a parenchymal haemorrhagic stroke is made by the
attending neurologist. Assuming the patient survives
this critical bleeding, what is the recommendation for
anticoagulation use after this complication?
What is in the ESC guidelines?
The AF guidelines do not provide any specific recom-
mendations on the use of DOACs after a haemorrhagic
stroke [1]. There is a general recommendation sug-
gesting that re-initiation of oral anticoagulation after
a bleeding event should be considered in all eligible
patients by a multidisciplinary team, considering dif-
ferent anticoagulants and stroke prevention interven-
tions [1].
Background
The risk of stroke in AF patients is considerable de-
spite anticoagulant treatment. In the case of is-
chaemic stroke, current management foresees the use
of catheter-guided clot removal, often in association
with thrombolytic treatment. In patients receiving
anticoagulation, the use of thrombolytic agents is,
however, not deemed safe. Only in the absence of
detectable anticoagulant activity in blood, such as
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a low INR in patients on a VKA, is thrombolytic ther-
apy considered. For DOACs, this remains a challenge
in the absence of a good point-of-care test (except
for dabigatran, which can be ruled out with a normal
thrombin clotting time) [20]. However, it is gener-
ally considered that when a patient has normal renal
function and the last dose was more than 24h ago
there is no contra-indication. In a post hoc analy-
sis of the ROCKET AF study of 19 patients receiving
thrombolytic therapy, mainly for ischaemic stroke, it
was shown that non-fatal major bleeding and death
occurred in 2 and 2 patients, respectively. These
events mostly occurred when thrombolytic therapy
was administered within 48h of the last rivaroxaban
dose [21]. Of the 9 patients in the warfarin group,
1 experienced a non-fatal major bleeding event and
3 died, most occurring when thrombolytic therapy
was administered more than 48h after the last war-
farin dose. This study suggests that careful assessment
of the time since the last dose may be of clinical sig-
nificance in patients on DOACs who require emergent
thrombolysis. In addition, some routine laboratory
tests can be used to exclude the presence of significant
levels of a DOAC, such as the diluted thrombin time,
which is highly sensitive for dabigatran [22]. Another
theoretical possibility is the use of a DOAC antidote
before thrombolysis, although there is currently little
support for this practice among neurologists.
Current recommendations on (re-) starting oral
anticoagulation after acute ischaemic stroke must
weigh (recurrent) stroke risk against secondary haem-
orrhagic transformation. After an acute ischaemic
stroke it is probably safe to re-start anticoagulation
after 1–14 days, depending on bleeding risk factors,
including the use of thrombolytic agents [23, 24].
A recent meta-analysis showed that resuming an-
ticoagulation 4–8 weeks after an intracranial bleed
is associated with fewer ischaemic strokes and that
there is no increased risk of re-bleeding [25, 26]. Cur-
rently, a Dutch trial is including patients with a history
of AF and a recent intracerebral haemorrhage dur-
ing treatment with anticoagulation (APACHE-AF, clin-
icaltrials.gov: NCT02565693). These patients are ran-
domly assigned in a 1:1 ratio to either apixaban or no
oral anticoagulation.
Consensus of advisory board
The consensus is that a full dosage of a DOAC can
be re-initiated 14 days after an ischaemic stroke,
provided that any risk factors for bleeding are not
persistent but manageable [27]. In the case of haem-
orrhagic stroke, anticoagulation could be re-initiated
after 4–8 weeks after careful consideration of the
pros and cons of anticoagulation, including type and
dosage.
Clinical situation D: patients who have
a malignancy and AF
Clinical case scenario
A 55-year-old man with AF, hypertension and diabetes
mellitus has been diagnosed with gastric cancer. He
is admitted to the emergency department with hae-
matemesis for which urgent endoscopy is indicated.
The attending gastroenterologist calls to discuss the
patient’s active DOAC use. What are the options for
this patient?
What is in the ESC guidelines?
Malignancy is considered a risk factor for bleeding in
the latest ESC guidelines on themanagement of AF [1].
Nevertheless, there are no clear recommendations in
the guideline with regard to the choice of a specific
type of oral anticoagulant for patients with an active
malignancy. The ESC guidelines do, however, rec-
ommend a cautious approach when using DOACs in
combination with systemic anticancer therapies that
influence CYP3A4 or P-glycoprotein to avoid under-
or overdosing.
Background
If a patient with AF develops cancer, clinicians should
carefully re-assess the risks of stroke versus bleeding.
In general, there are several options with regard to
the use of anticoagulation: continue anticoagulation
unchanged, switch from a DOAC to low-molecular-
weight heparin, reduce the dose of a DOAC or (tem-
porarily) discontinue oral anticoagulation in patients
deemed at high risk for bleeding, or stop anticoag-
ulation permanently in the case of a short life ex-
pectancy. One of the main issues of anticoagulation
in patients with a malignancy and DOAC is that the
risks of thromboembolism and bleeding vary widely
across tumour types, which complicates a ‘one size
fits all’ approach. Overall, in a prospective study, it
was shown that the AF-related thromboembolic risk
is not influenced by cancer status, but that patients
with active cancer do have an increased risk of bleed-
ing [28]. These bleeding events can be related to
the tumour itself (e.g. gastrointestinal, urinary tract,
or brain), diagnostic or therapeutic interventions, in-
creased anticoagulant drug levels due to kidney injury
(as a consequence of hypovolaemia or nephrotoxic
drugs), thrombocytopenia (e.g. due to chemother-
apy-induced bone marrow suppression), cancer treat-
ment (e.g. ibrutinib or bevacizumab), or due to in-
teraction with concomitant CYP3A4 or P-glycoprotein
inhibitors. However, in a post hoc analysis of the
ROCKET AF trial, it was shown that the safety and
efficacy of rivaroxaban treatment for AF in patients
with active cancer are comparable with the results of
the ROCKET AF study in the general population (al-
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beit that particular subtypes of cancer, e.g. gastric
cancer, may yield a higher risk for bleeding) [29]. Also
a subanalysis of the ENGAGE AF-TIMI 48 trial showed
that in patients with AF who develop malignancy, the
efficacy and safety profile of edoxaban relative to war-
farin is preserved [30]. Patients with a gastrointestinal
malignancy have a higher risk for anticoagulation-re-
lated bleeding, especially when using a DOAC [31].
Consensus of advisory board
It is the opinion of the advisory board that in general
anticoagulation should be continued unchanged in
patients with AF and cancer. Temporarily switching
from oral anticoagulation to low-molecular-weight
heparin is an alternative when patients are unable
to orally ingest drugs (e.g. due to nausea) or in the
presence of a significant drug-drug interaction. Fur-
thermore, a DOAC is not preferred in patients with
a luminal gastrointestinal cancer, and possibly also
Fig. 3 Framework for the initiation of direct oral anticoagu-
lant (DOAC). OAC oral anticoagulant
not in patients with urogenital cancer (although in
this case there is only limited data). In such patients,
switching from DOAC treatment to a reasonable al-
ternative, such as a VKA or low-molecular-weight
heparin, should be considered. Finally, anticoagulant
therapy should generally be discontinued in the case
of severe thrombocytopenia (<50× 109/l, or consider
platelet transfusion), abnormal liver function, or se-
vere kidney injury (creatinine clearance <30ml/min);
however, then a VKA is still an option.
Conclusions
In this article, by providing four case scenarios we
tried to summarise the evidence for managing several
major dilemmas we often encounter in clinical prac-
tice and for which current guidelines on antithrom-
botic therapy do not provide clear recommendations,
or where new data has been published recently. Fig. 3
shows a framework which may help in decision mak-
ing in the clinical setting. It is important to remember
that our advice is to use a full-dose regimen of a DOAC
if possible, as this is the dosage investigated in the
major DOAC trials, but that the dosage may need to
be individualised under specific circumstances, albeit
there are no supporting data. Resuming anticoagula-
tion is in general recommended, provided there are
no persistent risk factors for bleeding that exceed the
risk of thromboembolism.
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